Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ELTX
ELTX logo

ELTX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Elicio Therapeutics Inc (ELTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
12.030
1 Day change
0.42%
52 Week Range
14.930
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Elicio Therapeutics Inc (ELTX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows strong technical momentum, positive analyst sentiment, and promising clinical developments in its pipeline. Despite weak financials, the company's innovative technology and potential in addressing high-need cancer indications make it a compelling long-term opportunity.

Technical Analysis

The stock is in a strong bullish trend with MACD histogram at 0.168 (positively expanding), RSI at 83.131 (overbought), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are R1: 12.369 and R2: 13.085, while support levels are S1: 10.05 and S2: 9.334. The stock closed at $12.8, above the pivot level of $11.209, indicating strong upward momentum.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • Analysts are bullish with multiple Buy ratings and increased price targets (up to $20).

  • Promising clinical outcomes for ELI-002 in mKRAS-positive pancreatic and colorectal cancers.

  • Innovative Amphiphile technology for faster and cost-effective immunotherapy.

  • Positive sentiment in options data with low put-call ratios and high call volume.

Neutral/Negative Catalysts

  • Weak financial performance with declining net income (-44.89% YoY) and EPS (-51.46% YoY).

  • Overbought RSI (83.

  • may indicate a potential short-term pullback.

Financial Performance

In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$7.72M (-44.89% YoY), and a significant EPS drop to -0.5 (-51.46% YoY). Gross margin remained at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly positive on ELTX. Ladenburg initiated a Buy rating with a $20 price target, citing the company's potential to set a new standard of care in pancreatic cancer. H.C. Wainwright raised its price target to $17 from $13, increasing the probability of success for ELI-002 to 50%. Rodman & Renshaw also issued a Buy rating with a $17 price target, highlighting ELI-002 as a paradigm shift in mKRAS immunotherapy.

Wall Street analysts forecast ELTX stock price to rise
2 Analyst Rating
Wall Street analysts forecast ELTX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.850
sliders
Low
13
Averages
15.5
High
18
Current: 11.850
sliders
Low
13
Averages
15.5
High
18
Ladenburg
Buy
initiated
$20
AI Analysis
2026-04-15
Reason
Ladenburg
Price Target
$20
AI Analysis
2026-04-15
initiated
Buy
Reason
Ladenburg initiated coverage of Elicio Therapeutics with a Buy rating and $20 price target. The firm says the company is creating the new standard of care in minimal residual disease positive pancreatic cancer.
H.C. Wainwright
Buy
maintain
$13 -> $17
2026-03-13
Reason
H.C. Wainwright
Price Target
$13 -> $17
2026-03-13
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Elicio Therapeutics to $17 from $13 and keeps a Buy rating on the shares. To reflect the data seen to date, the firm increased its probability of success for ELI-002 to 50% from 30%.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ELTX
Unlock Now

People Also Watch